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Introduction
The optimal immunosuppressive treatment in patients
with systemic lupus erythematosus (SLE) remains contro-
versial [1]. Mycophenolate mofetil (MMF) has proved to
be an efficacious and safe therapy in adult lupus nephritis
[2]. Recently, this drug has been suggested as a possible
new alternative treatment for juvenile-SLE, especially in
cases of lupus nephritis refractory to treatment with cor-
ticosteroids, cyclophosphamide azathioprine, methotrex-
ate and/or cyclosporine [3-4]. In this review we describe
our experience with six children diagnosed with SLE and
treated with MMF.
Aim
To report the clinical experience of a single center in
the use of MMF in refractory juvenile SLE.
Patients and methods
Chart review of refractory juvenile SLE treated with
MMF in the pediatric rheumatology outpatient clinic of
Santa Maria Hospital.
Results
Six children with juvenile SLE (five girls and one boy)
with a mean age of 13.8 years (range 10-16) were treated
with MMF at a dose of 0.5 to 2.5g/dl daily for a period of
6 to 29 months (mean 17.5±11.6). Patients were followed
for 5.2±2.2 years. The average disease duration was of 3.5
±2.1 years at the beginning of the MMF treatment. All
patients had kidney involvement; three of them had con-
comitant severe central nervous system involvement and
two antiphospholipid syndrome. Five patients were
biopsy-proven severe lupus nephritis (three with class IV
and two with class V). One patient had thrombotic
thrombocytopenic purpura associated to SLE. All
patients were previously treated with high dose steroids,
four of them started ciclophosphamide (CYC) pulses and
one received rituximab (RTX).Five patients began MMF
as induction therapy in renal involvement and only one
as maintenance therapy. MMF was effective in reducing
disease activity and as a steroid-sparing agent in half of
the patients. The responders experienced a marked
r e d u c t i o ni nS L E D A Is c o r e ,i na n t i - d s D N Aa n t i b o d y
titers and an improvement in serum complements levels.
One patient stopped MMF therapy due to gastrointest-
inal intolerance and another one reduced the dose due to
leucopenia.
Conclusion
MMF appeared to be effective and safe in controlling
disease activity in some refractory juvenile SLE. It also
showed a significant steroid sparing effect.
Author details
1Serviço de Reumatologia e Doenças Ósseas Metabólicas, CHLN - Hospital
de Santa Maria; Lisbon, Portugal.
2Unidade de Investigação em
Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina da
Universidade de Lisboa e Serviço de Reumatologia e Doenças Ósseas
Metabólicas, CHLN- Hospital de Santa Maria, Lisbon, Portugal.
3Unidade de
Nefrologia Pediátrica do Serviço de Pediatria, CHLN - Hospital de Santa
Maria, Lisbon, Portugal.
Published: 25 November 2010
References
1. Pereira J, Ferreira F, Rodrigues AM, et al: Rituximab Use in Pediatric
Autoimmune Diseases Four Case Reports. Ann N Y Acad Sci 2009, 1-9.
2. Fujinaga S: Maintenance therapy with mycophenolate mofetil for
children with severe lupus nephritis after low-dose intravenous
cyclophosphamide regimen. 2008, 23(10):1877-82, Epub.
1Serviço de Reumatologia e Doenças Ósseas Metabólicas, CHLN - Hospital
de Santa Maria; Lisbon, Portugal
Full list of author information is available at the end of the article
Marques et al. Journal of Translational Medicine 2010, 8(Suppl 1):P73
http://www.translational-medicine.com/content/8/S1/P73
© 2010 Marques and Ponte; licensee BioMed Central Ltd.3. Marks SD, Tullus K: Modern therapeutic strategies for paediatric systemic
lupus erythematosus and lupus nephritis. Acta Paediatr 2010, Mar 11.
4. Dittrich K: Experience with mycophenolate mofetil as maintenance
therapy in five pediatric patients with severe systemic lupus
erythematosus. Klin Padiatr 2009, 221(7):425-9.
doi:10.1186/1479-5876-8-S1-P73
Cite this article as: Marques et al.: Mycophenolate mofetil use in
refractory juvenile systemic lupus erythematosus. Journal of Translational
Medicine 2010 8(Suppl 1):P73.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Marques et al. Journal of Translational Medicine 2010, 8(Suppl 1):P73
http://www.translational-medicine.com/content/8/S1/P73
Page 2 of 2